{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:17:07Z","timestamp":1788797827939,"version":"build-2803163510"},"reference-count":39,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Efficacy of ranolazine in the treatment of chronic stable angina (CSA) has been established; however, pivotal trials did not require the optimization of conventional antianginal drug therapy (CADT) prior to use in a veteran population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To determine whether ranolazine, when added to optimized doses of CADT, improves angina in a veteran population with CSA and refractory symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>In an observational retrospective study, 35 patients prescribed ranolazine and having a baseline Seattle Angina Questionnaire (SAQ) administered at a Veterans Affairs medical center in Gainesville, FL, were evaluated. Patients who were prescribed ranolazine by a provider from outside the institution and did not obtain a baseline SAQ were excluded. The primary outcome measure was the change in SAQ scores from baseline to 1 and 3 months after initiation of ranolazine treatment. Secondary measures included clinically significant QTc interval prolongation (&gt;500 msec or an increase of at least 60 msec from baseline), adverse drug reactions, discontinuation rates, and drug-drug interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>The addition of ranolazine to optimized CADT was associated with improvement in all dimensions of the SAQ scores at 1 and 3 months compared to baseline scores (p &lt; 0.001 for all dimensions). Mean changes in SAQ dimension scores at 1 and 3 months, respectively, were as follows: physical limitation, +9.86 and +11.94; angina stability, +39.29 and +32.69; angina frequency, +26.79 and +25.38; treatment satisfaction, +11.38 and +10.66; and disease perception, +16.85 and +18.59. Improvments in all dimensions, except treatment satisfaction, were clinically significant as defined by set criteria. Of the 7 patients whose ranolazine dosages were increased to 1000 mg twice daily, only 2 patients were able to maintain treatment at that dosage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Ranolazine added to optimized doses of CADT demonstrated an improvement in angina symptoms when given to a veteran population with persistent CSA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1q487","type":"journal-article","created":{"date-parts":[[2012,1,4]],"date-time":"2012-01-04T03:59:59Z","timestamp":1325649599000},"page":"42-50","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Experience with Ranolazine in a Veteran Population with Chronic Stable Angina"],"prefix":"10.1177","volume":"46","author":[{"given":"Don N","family":"Reeder","sequence":"first","affiliation":[{"name":"Don N Reeder PharmD, Clinical Pharmacy Specialist, Malcom Randall Veterans Affairs Medical Center, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Gillette","sequence":"additional","affiliation":[{"name":"Michael A Gillette PharmD BCPS, Post-Doctoral Fellow in Cardiology and Critical Care, Malcom Randall Veterans Affairs Medical Center; College of Pharmacy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Franck","sequence":"additional","affiliation":[{"name":"Andrew J Franck PharmD BCPS, Clinical Pharmacy Specialist, Malcom Randall Veterans Affairs Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Frohnapple","sequence":"additional","affiliation":[{"name":"David J Frohnapple PharmD BCPS BCNSP, Director, Post-Doctoral Fellowship in Cardiology\/Critical Care and Post-Graduate Year 2 Critical Care Residency; Clinical Pharmacy Specialist, Medical Intensive Care Unit\/Total Parenteral Nutrition Service, Malcom Randall Veterans Affairs Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,1,1]]},"reference":[{"key":"bibr1-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182009701"},{"key":"bibr2-aph.1Q487","volume-title":"Chronic Stable Angina Writing Committee; American College of Cardiology","author":"Fraker TD","year":"2002"},{"key":"bibr3-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.05.029"},{"key":"bibr4-aph.1Q487","first-page":"e1","volume":"50","year":"2007","journal-title":"erratum"},{"key":"bibr5-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.295"},{"key":"bibr6-aph.1Q487","unstructured":"4Gibbons RJ, Abrams J, Chatterjee K American College of Cardiology\/American Heart Association 2002 guideline update for the management of patients with chronic stable angina. www.acc.org\/qualityandscience\/clinical\/statements.htm (accessed 2011 Aug 8)."},{"key":"bibr7-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.829523"},{"key":"bibr8-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.01.037"},{"key":"bibr9-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.6.626"},{"key":"bibr10-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198711000-00008"},{"key":"bibr11-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198512000-00005"},{"key":"bibr12-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03430070055030"},{"key":"bibr13-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1177\/106286069901400105"},{"key":"bibr14-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2011.04.310"},{"key":"bibr15-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.02.044"},{"key":"bibr16-aph.1Q487","volume-title":"Package insert. Ranexa (ranolazine)","year":"2006"},{"key":"bibr17-aph.1Q487","first-page":"1","volume":"98","author":"Sossalla ST","year":"2009","journal-title":"Clin Res Cardiol"},{"key":"bibr18-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181a1b9e7"},{"key":"bibr19-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000139333.83620.5D"},{"key":"bibr20-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.04.042"},{"key":"bibr21-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61554-8"},{"key":"bibr22-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.12.1659"},{"key":"bibr23-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.11.045"},{"key":"bibr24-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.309"},{"key":"bibr25-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.05.044"},{"key":"bibr26-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.12.1677"},{"key":"bibr27-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp042317"},{"key":"bibr28-aph.1Q487","first-page":"2728","volume":"353","year":"2005","journal-title":"erratum"},{"key":"bibr29-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)00397-9"},{"key":"bibr30-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90555-X"},{"key":"bibr31-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.001"},{"key":"bibr32-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072771"},{"key":"bibr33-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.10.039"},{"key":"bibr34-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.187397"},{"key":"bibr35-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.16.1775"},{"key":"bibr36-aph.1Q487","first-page":"264","volume":"10","author":"Rifkin SI","year":"2008","journal-title":"Medscape J Med"},{"key":"bibr37-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645050-00003"},{"key":"bibr38-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004273992"},{"key":"bibr39-aph.1Q487","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090299"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1Q487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1Q487","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1Q487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:09:08Z","timestamp":1777374548000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1Q487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1345\/aph.1Q487"],"URL":"https:\/\/doi.org\/10.1345\/aph.1q487","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}